“Hyperphosphatemia, a much-debated complication of IV iron treatment, was reported in only 1 RCT of FCM, in this case transient and clinically asymptomatic,” the authors reported.

The risk of anaphylaxis across all five IV iron formulations was still very low, he noted, but the data shows that the highest incidence was noted for iron dextran, with 10 patients per 10,000 ...

The risk for anaphylaxis from IV iron formulations appeared low, although it varied depending on the type of treatment being administered, according to a study published in Annals of Internal ...

The highest adjusted incidence rates for anaphylaxis among Medicare recipients receiving IV iron was 9.8 cases (95% CI 6.2-15.3) per 10,000 first administrations of iron dextran (Dexferrum) and 4. ...

June 16, 2009 (Seattle, Washington) — A double-blind, placebo-controlled study shows that intravenous (IV) iron, specifically ferric carboxymaltose (FCM), is a safe and effective treatment for ...

CHICAGO, Nov. 5, 2022 — Long-term treatment with iron administered intravenously improved symptoms and reduced recurrent hospitalizations among people with heart failure and iron deficiency ...

September 15, 2008 (Stockholm, Sweden) — In patients with chemotherapy-induced anemia, the addition of intravenous (IV) iron to an erythropoiesis-stimulating agent (ESA) improves the hematologic ...

Among patients undergoing maintenance hemodialysis, high-dose IV iron reduced the rate of fatal or nonfatal MIs over 2 years compared with lower-dose iron, according to an analysis of the PIVOTAL ...

NKF 2017-IV Medication drip in hospital To support ESA therapy, IV iron at doses below 300 mg/month may be most effective for the average hemodialysis patient, according to an observational study ...